Abstract:Esophageal carcinoma (EC) ranks among the top six most prevalent malignancies worldwide with a recent surge in incidence. An innovative integrated omics technique is presented for discerning the two primary types of esophageal carcinoma (EC) AND Squamous cell carcinoma and adenocarcinoma. Utilizing The Cancer Genome Atlas (TCGA) data via Bioconductor, the research integrated DNA methylation and RNA expression analyses for esophageal cancer (ESCA). Key findings revealed DNA methylation’s pivotal role in ESCA progression and its potential as an early detection biomarker. Significant disparities in methylation patterns offered insights into the disease’s pathogenesis. A comparison with the TCGA Pan-Cancer dataset using Bioconductor tools enriched the understanding of ESCA genomics. Specifically, 131,220 hypomethylated probes were detected in tumors compared to 6,248 in healthy tissues. Additionally, 42,060 probe-gene pairs linked methylation variations to expression alterations, with 768 hypomethylated motifs identified. Thirteen of these motifs emerged as potential diagnostic markers. Transcription factor analyses spotlighted crucial regulators, including NFL3, ATF4, JUN, and CEBPG, revealing intricate regulatory networks in ESCA. Survival statistics further correlated clinical factors with patient longevity. This research recommends an innovative approach to identifying oesophageal abnormalities through DNA methylation and gene expression mechanisms. Research suggests DNA methylation may serve as an early detection biomarker, aiding in identifying esophagus cancer prior to more advanced stages. ### Competing Interest Statement The authors have declared no competing interest. ### Clinical Trial "N/A" ### Clinical Protocols ### Funding Statement The work is self funded. my country blongs to group B global assistant program. I am the author of the manucript and i will apply for research group which will cover all the publication fee. ### Author Declarations I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained. Yes The details of the IRB/oversight body that provided approval or exemption for the research described are given below: Our research adhered to high ethical standards, having received approval from the Institutional Review Board (IRB). This work was supported by the Liaoning Province Rejuvenating Talents Plan (No: XLYC2002045), the Key R&D Program of Liaoning Province (No: 2019JH2/10300041), Scientific Research Project from the Department of Education of Liaoning Province (No. LJKZ0088 and LQN201906), the National Natural Science Foundation of China (No: 82003655) and Shenyang Science and Technology Project (No. 21-116-3-48 and RC210216). The research did not entail any conflicts of interest and all financial support. The data collected during this study will be made available upon request, following the guidelines set by MedRxiv for data sharing. Each author contributed significantly to the execution of this research and the preparation of the manuscript, underlining a collective commitment to ethical research and reporting practices. I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals. Yes I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance). Yes I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable. Yes Upon the acceptance of this manuscript for publication, the supporting data and associated code will be made publicly available on GitHub for the benefit of the research community. Interested researchers can access these resources at the following repository: .

Identification of a DNA Methylome Profile of Esophageal Squamous Cell Carcinoma and Potential Plasma Epigenetic Biomarkers for Early Diagnosis

Genome-wide profiling of DNA methylation and gene expression in esophageal squamous cell carcinoma

Multi-omic characterization of genome-wide abnormal DNA methylation reveals diagnostic and prognostic markers for esophageal squamous-cell carcinoma

The Detective, Prognostic, and Predictive Value of DNA Methylation in Human Esophageal Squamous Cell Carcinoma

Genome-Wide DNA Methylation Profiling of Esophageal Squamous Cell Carcinoma from Global High-Incidence Regions Identifies Crucial Genes and Potential Cancer Markers

Genome-Wide DNA Methylation and Gene Expression Profiling Characterizes Molecular Subtypes of Esophagus Squamous Cell Carcinoma for Predicting Patient Survival and Immunotherapy Efficacy

Identification of DNA methylation-driven genes in esophageal squamous cell carcinoma: a study based on The Cancer Genome Atlas

Targeted Bisulfite Sequencing Identified a Panel of DNA Methylation-Based Biomarkers for Esophageal Squamous Cell Carcinoma (ESCC)

Identification of Hyper-Methylated Tumor Suppressor Genes-Based Diagnostic Panel for Esophageal Squamous Cell Carcinoma (ESCC) in a Chinese Han Population

Novel DNA methylation markers for early detection of gastric cardia adenocarcinoma and esophageal squamous cell carcinoma

Dna Methylation Status Of Pax1 And Znf582 In Esophageal Squamous Cell Carcinoma

Genome-Scale Multimodal Analysis of Cell-Free DNA Whole-Methylome Sequencing for Noninvasive Esophageal Cancer Detection

DNA methylation markers in esophageal cancer

Inter- and intratumor DNA methylation heterogeneity associated with lymph node metastasis and prognosis of esophageal squamous cell carcinoma

Combined Detection of Plasma ZIC1, HOXD10 and RUNX3 Methylation is a Promising Strategy for Early Detection of Gastric Cancer and Precancerous Lesions.

Genome-wide methylation profiling identified methylated KCNA3 and OTOP2 as promising diagnostic markers for esophageal squamous cell carcinoma

Discovery and validation of methylation signatures in circulating cell-free DNA for early detection of esophageal cancer: A case-control study.

DNA Methylome and Transcriptome Analysis Established a Model of Four Differentially Methylated Positions (dmps) As a Diagnostic Marker in Esophageal Adenocarcinoma Early Detection.

Circulating cell-free DNA-based methylation pattern in plasma for early diagnosis of esophagus cancer

Identification of Plasma Metabolomic Profiling for Diagnosis of Esophageal Squamous-Cell Carcinoma Using an UPLC/TOF/MS Platform

Unlocking Esophageal Carcinoma’s Secrets: an Integrated Omics Approach Unveils DNA Methylation As a Pivotal Early Detection Biomarker with Clinical Implications